Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm).

1068Background: ALP was approved by the FDA for treatment of HR+/HER2- advanced BC with activating PIK3CAm based on the phase 3 SOLAR-1 trial. Enrollment used 11 PIK3CAm (SOLAR1m) in PIK3CA exons 7...